Weight-Loss Pills vs Injections: Which?

Neither route is automatically better: the molecule, approved use, risks and routine matter more than the route. In separate trials, oral semaglutide 25 mg averaged 13.6% weight loss at 64 weeks (OASIS 4) and weekly semaglutide 2.4 mg injections averaged 14.9% at 68 weeks (STEP 1, NEJM 2021). Those are trial results, not REMEVi averages.

Are weight-loss pills or injections more effective?

Quick answer: Route alone cannot rank medicines. In trials, results differed by molecule, dose and population, and separate trials cannot be compared directly.

Trials inform the studied product, dose and population. Comparing percentages across different trials does not establish treatment equivalence, and it does not establish that one route works better. Different populations, protocols and handling of missing data limit those comparisons.

Medicine and route	Trial	Average weight change in the trial	Placebo
Semaglutide 2.4 mg, weekly injection (Wegovy)	STEP 1, NEJM 2021, 68 weeks	−14.9%	−2.4%
Tirzepatide 15 mg, weekly injection (Zepbound)	SURMOUNT-1, NEJM 2022, 72 weeks	−20.9%	−3.1%
Oral semaglutide 25 mg, daily tablet (Wegovy tablets)	OASIS 4, 64 weeks	−13.6%	−2.2%
Orforglipron, highest approved dose, daily tablet (Foundayo)	Foundayo label, Table 6, 72 weeks	−11.1%	−2.1%

These are group averages for brand medicines in their own trials; participants had differing responses and some stopped treatment. The current Wegovy label’s Study 7 table reports a −2.4% placebo change with its specified analysis, while the OASIS 4 publication reports −2.2%; do not combine figures from different analyses. In particular, OASIS 1 studied oral semaglutide 50 mg: it should not be presented as the approved Wegovy tablet dose or as evidence for a compounded preparation. Wegovy label, section 14.2

Which weight-loss pills are FDA-approved?

Quick answer: Long-term options include orlistat, phentermine/topiramate, naltrexone/bupropion, Wegovy tablets and, since April 1, 2026, Foundayo (orforglipron).

Long-term weight-management options include orlistat, phentermine/topiramate, naltrexone/bupropion and Wegovy tablets. FDA also approved Foundayo (orforglipron) on April 1, 2026. It is therefore no longer accurate to describe Wegovy as the only oral GLP-1 option for obesity. Indications, precautions and approved ages depend on the product. FDA: Foundayo approval Contrave: prescribing information Adipex-P: prescribing information Wegovy: prescribing information

The FDA-approved injectable options for long-term weight management include weekly semaglutide (Wegovy) and tirzepatide (Zepbound), and daily liraglutide (Saxenda). For more detail, see our guides to FDA-approved weight-loss pills and how to choose a weight-loss medication.

How do the pill and injection classes work?

Quick answer: GLP-1 medicines come as pills and injections and act on appetite and glucose regulation; orlistat reduces fat absorption; other pills use different appetite pathways.

Orlistat reduces fat absorption. Phentermine/topiramate and naltrexone/bupropion use other appetite-related pathways. GLP-1 receptor agonists influence appetite and glucose regulation. Phentermine alone is approved for short-term use; it should not be confused with a combination approved for long-term use. Source: NIDDK: prescription weight-management medicines

How do daily routines differ between pills and injections?

Quick answer: Injections are weekly or daily shots; pills are daily, and some, like Wegovy tablets, have strict fasting and water instructions while others do not.

Route alone cannot rank medicines by effectiveness or tolerability. Administration rules also vary: semaglutide tablets have fasting instructions, but not every pill shares that schedule. A milligram dose of one product does not equal the same number for another. Do not convert oral and injectable doses yourself.

Product	Route and frequency	Routine to plan around
Wegovy injection; Zepbound	Weekly injection	One injection on a schedule, with training for the pen or device
Saxenda	Daily injection	A daily injection
Wegovy tablets	Daily tablet	Morning, on an empty stomach, with up to four ounces of water, then at least 30 minutes before food, drinks or other oral medicines
Foundayo	Daily tablet	May be taken with or without food
Orlistat (Xenical; alli)	Oral, linked to meals	Oily stools and urgency can affect your routine

Sources: Wegovy label, section 2.1, Foundayo label, section 2, NIDDK. Neither tablet schedule is an instruction for a compounded oral preparation.

Is compounded oral semaglutide an approved tablet?

Quick answer: No. A compounded oral preparation is not Wegovy, Ozempic or Rybelsus and does not share their FDA approval or established clinical equivalence.

A compounded oral preparation is not Wegovy, Ozempic or Rybelsus and does not have their approval. Approval of a molecule in one product does not transfer to another formulation, and branded-trial results do not establish results for a compounded preparation. Source: FDA: unapproved GLP-1 medicines

What should you ask your clinician about pills vs injections?

Quick answer: Ask about the exact product’s indication, your history and interactions, risks, daily routine, ongoing cost, follow-up, and how response will be assessed.

Review the indication, history, interactions, risks, daily routine, ongoing cost and follow-up. Ask how response will be assessed and when the plan would change. Review REMEVi’s oral semaglutide options, which are compounded preparations distinct from approved tablets. For REMEVi’s program charges, see current pricing.